Sort
40,608 grants matching “prostate cancer”
Growth Factors and Lethal Prostate Cancer Signature
$563,130Meir J Stampfer · Brigham And Women'S Hospital · R01 · FY2012 · CA
Humanized bone marrow-like model to study patient-derived myeloma xenografts
$563,030Constantine S. Mitsiades · Dana-Farber Cancer Inst · R01 · FY2016 · CA
Prostate Cancer Diagnosis by Multiparametric Ultrasound
$562,920Flemming Forsberg · Thomas Jefferson University · R01 · FY2024 · CA
Mammalian Target of Rapamycin in Prostate Carcinogenesis
$562,905Jeffrey Michael Arbeit · Washington University · R01 · FY2007 · CA
Molecular Pathology of Cancer
$562,873Michael Emmert-Buck · Division Of Clinical Sciences - Nci · ZIA · FY2013 · CA
Outcomes of Triaged Family Care in Advanced Cancer
$562,848University Of Michigan At Ann Arbor · R01 · FY2004 · CA
ROBOT FOR IMAGE-TARGETED PROSTATE CANCER BIOPSY
$562,846The Johns Hopkins University · · FY2008 · Department of the Army
Genetic determinants of gene expression phenotypes in aggressive prostate cancer
$562,767Liang Wang · Medical College Of Wisconsin · R01 · FY2015 · CA
FUNCTIONAL VALIDATION OF H2 RELAXIN AND ITS DOWNSTREAM EFFECTORS AS MEDIATORS, THERAPEUTIC TARGETS & POTENTIAL BIOMARKERS OF PROSTATE CANCER PROGRESS
$562,677University Of California, Davis · · FY2008 · Department of the Army
Western Regional Community Clinical Oncology Program
$562,644Banner Good Samaritan Medical Center · U10 · FY2004 · CA
Atlanta Regional Community Clinical Oncology Program (ARCCOP)
$562,599Thomas E Seay · St. Joseph'S Hospital · U10 · FY2012 · CA
COTARGETING OF ANDROGEN SYNTHESIS AND ANDROGEN RECEPTOR EXPRESSION AS A NOVEL TREATMENT FOR CASTRATION-RESISTANT PROSTATE CANCER
$562,579Purdue University · · FY2016 · Department of the Army
Testing ATAD2 as a new therapeutic target for advanced prostate cancer
$562,551Tanya I Stoyanova · University Of California Los Angeles · R01 · FY2024 · CA
Hexokinase 2 and cancer therapy
$562,533Nissim Hay · University Of Illinois At Chicago · R01 · FY2023 · CA
Hexokinase 2 and cancer therapy
$562,533Nissim Hay · University Of Illinois At Chicago · R01 · FY2022 · CA
TARGETING THE REACTIVE STROMA NICHE IN PROSTATE CANCER
$562,500Baylor College Of Medicine · · FY2008 · Department of the Army
THE ROLE OF TYROSINE KINASE ETK IN CHEMORESISTANCE OF PROSTATE CANCER
$562,500University Of Maryland, Baltimore · · FY2008 · Department of the Army
THE ROLE OF EZH2 IN PROSTATE CANCER PROGRESSION
$562,500University Of Maryland, Baltimore · · FY2008 · Department of the Army
A NOVEL THERAPEUTIC MODALITY FOR ADVANCED-STAGE PROSTATE CANCER TREATMENT
$562,500University Of Tennessee · · FY2014 · Department of the Army
A NOVEL STRATEGY FOR PROSTATE CANCER THERAPY TARGETING THE C-MYC ONCOPROTEIN
$562,500University Of Florida · · FY2014 · Department of the Army
Increasing the diagnostic yield of low-risk bronchial biopsy in the evaluation of
$562,380Melissa J Suter · Massachusetts General Hospital · R01 · FY2017 · CA
ARCHER - An Extremely Fast Medical Radiation Dose Computing Software
$562,280Xie George Xu · Virtual Phantoms, Inc. · R42 · FY2017 · EB
Commonly Used Medications and Risk of Colorectal Cancer Recurrence
$562,249Jessica Chubak · Kaiser Foundation Health Plan Of Washington · R01 · FY2014 · CA
Advanced PET/CT Imaging for Improving Clincail Trials
$562,213Paul E Kinahan · University Of Washington · U01 · FY2012 · CA
CD24 AS A POTENTIAL THERAPEUTIC TARGET IN PROSTATE CANCER
$562,200Regents Of The University Of Michigan · · FY2008 · Department of the Army